Opus Genetics (IRD) Cash from Financing Activities (2011 - 2026)
Opus Genetics (IRD) posted quarterly Cash from Financing Activities of $27.6 million for Q1 2026, up 34.84% year-over-year from $20.5 million in Q1 2025, and up 14.46% quarter-over-quarter from $24.1 million in Q4 2025.
Powered by 
Analysis
Opus Genetics (IRD) Cash from Financing Activities (2011 - 2026) Analysis & Trends
Opus Genetics (IRD) has reported Cash from Financing Activities for 14 consecutive years, with $27.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 34.84% year-over-year to $27.6 million; the TTM figure through Mar 2026 stood at $57.2 million (up 156.58% YoY), while the FY2025 annual figure was $50.0 million, up 1095.01% from the prior year.
- Cash from Financing Activities grew to $27.6 million in Q1 2026 per IRD's latest filing, from $24.1 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $27.6 million in Q1 2026 and bottomed at -$83000.0 in Q4 2024.
- Historically, Cash from Financing Activities has averaged $6.3 million across 5 years, with a median of $1.6 million in 2022.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities surged 30125.0% — and 2024, when it plunged 102.3%.
- Opus Genetics' Cash from Financing Activities stood at -$12000.0 in 2022, then soared by 30125.0% to $3.6 million in 2023, then tumbled by 102.3% to -$83000.0 in 2024, then soared by 29146.99% to $24.1 million in 2025, then climbed by 14.46% to $27.6 million in 2026.
- Business Quant data shows IRD's Cash from Financing Activities at $27.6 million in Q1 2026, $24.1 million in Q4 2025, and $4.5 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 14.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.42 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -6.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 36.24 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -273.15 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Opus Genetics | 446.86 Mn | 358.05 Mn | - | 40.90 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 40.90 Mn |
| Mar 31, 2026 | 27.60 Mn |
| Dec 31, 2025 | 24.11 Mn |
| Sep 30, 2025 | 4.54 Mn |
| Jun 30, 2025 | 906,000.00 |
| Mar 31, 2025 | 20.47 Mn |
| Dec 31, 2024 | -83,000.00 |
| Sep 30, 2024 | 353,000.00 |
| Jun 30, 2024 | 1.54 Mn |
| Mar 31, 2024 | 2.38 Mn |
| Dec 31, 2023 | 3.60 Mn |
| Sep 30, 2023 | 5.38 Mn |
| Dec 31, 2022 | -12,000.00 |
| Sep 30, 2022 | 1.33 Mn |
| Jun 30, 2022 | 1.59 Mn |
| Mar 31, 2022 | 882,000.00 |
| Dec 31, 2021 | 8.03 Mn |
| Sep 30, 2021 | 1.60 Mn |
| Jun 30, 2021 | 17.97 Mn |
| Mar 31, 2021 | 10,000.00 |